Importantly, the upregulation of KLK5 and KLK7 activity by loss of the endogenous KLK inhibitor serine peptidase inhibitor Kazal type 5 (SPINK5) causes atopic dermatitis‐associated diseases, including Netherton syndrome (Furio & Hovnanian, 2014). Here, KLK5 is linked to atopic eczema.